Search
Returning search results with filters:
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
- 20231 results available
- 20222 results available
- 20215 results available
- 20162 results available
- 20124 results available
- 20092 results available
- 20073 results available
- 20064 results available
- 20054 results available
- 20043 results available
- 20032 results available
- 20025 results available
- 20011 results available
Displaying 1 - 15 of 38 items.
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
AlertHealth professional risk communication | 2021-06-29
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
AlertHealth professional risk communication | 2021-03-24
Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-03-01
Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-Labelled Supply)
AlertHealth professional risk communication | 2021-03-31
Authorization of COVISHIELD with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2021-03-01
Archived - For the Public - Important Safety Information on IRESSA (gefitinib) - AstraZeneca Canada Inc.
AlertHealth professional risk communication | 2007-05-14
Archived – Important Safety Information Regarding Accolate® (Zafirlukast) and Hepatic Effects – AstraZeneca
AlertHealth professional risk communication | 2002-12-18
Important Safety Information on Oxeze (formoterol fumarate dihydrate) Turbuhaler – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-09-09
Association of CRESTOR® (rosuvastatin) with Muscle -Related Adverse Events – AstraZeneca Canada Inc. – For Health Professionals
AlertHealth professional risk communication | 2005-03-11
Archived - Public Advisory: Liver Problems Associated With Use of ACCOLATE (zafirlukast) in Some Patients - AstraZeneca - For the Public
AlertHealth professional risk communication | 2002-12-18
Archived – Important Safety Information Concerning Liver Problems for Patients Taking ACCOLATE® (Zafirlukast) – AstraZeneca Canada Inc. – For the Public
AlertHealth professional risk communication | 2004-04-19
Archived – Important Safety Information Regarding Medication Errors Resulting From Confusion Between Seroquel and Serzone-5HT2 – AstraZeneca and Bristol-Myers Squibb – For the Public
AlertHealth professional risk communication | 2002-10-31
Archived – Important Safety Information Regarding Medication Errors Resulting from Confusion Between Seroquel® and Serzone-5HT2® – AstraZeneca and Bristol-Myers Squibb
AlertHealth professional risk communication | 2002-10-31
Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For Health Professionals
AlertHealth professional risk communication | 2012-07-26
Pulmicort Turbuhaler (budesonide) powder for oral inhalation - Potential device failure - For the Public
AlertHealth professional risk communication | 2012-07-26